Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept in Ocular Myasthenia Gravis
NCT07249632Phase 3Recruiting
- Sponsor
- RemeGen
- Start
- Jan 2026
- Primary completion
- Dec 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of telitacicept in myasthenia gravis (MG), sponsored by RemeGen. Started Jan 2026; status: recruiting.
02
Drugs
telitacicept
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT07249632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07249632.